+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Liver Disease Diagnostics Market By End User, By Diagnosis Technique, By Country, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5129441
  • Report
  • June 2020
  • Region: North America
  • 75 Pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
The North America Liver Disease Diagnostics Market is expected to witness market growth of 5.8% CAGR during the forecast period (2020-2026).

Liver transplantation is the second most common organ transplant in the world after liver transplant. However, less than 10% of the global demands for organ transplantation are being met at the current rate of transplantation. While these numbers are sobering, they provide a significant incentive to improve public health, considering that most causes of liver disease are preventable.

The contrast agent, gadoxetic acid, is administered into a peripheral vein. It is absorbed by the liver cells (hepatocytes) and removed by the bile ducts. Chronic inflammation of the liver tissue, such as viral hepatitis or fatty liver disease, may lead to scarring (fibrosis/cirrhosis) of the organ, leading to a reduction in the number of functioning hepatocytes and/or a decrease in the number of cellular transporters responsible for the absorption of the contrast agent into hepatocytes. It ultimately leads to a decreased reduction of the liver as a contrast agent. Radiation-free fMRI shows damage to the liver cell as decreased liver light and impaired excretion of the contrast agent in the bile ducts by serial imaging.

North America dominated the market in the regional market. High investment in R&D and the involvement of key players are expected to be responsible for the growth of the liver disease diagnostics market in the region. In addition, the existence of organizations offering information on the treatment of diseases to patients is expected to drive the growth of the liver disease diagnostics industry. One such agency is GetPalliativeCare.org, which provides information on palliative care related to medical procedures such as endoscopy, CT scan, and biopsy.

Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.

Scope of the Study

Market Segmentation:

By End User
  • Hospitals, Laboratories and Other End Users

By Diagnosis Technique
  • Imaging
  • Biopsy
  • Endoscopy
  • Laboratory tests and
  • Other Diagnosis Techniques

By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Boston Scientific Corporation
  • Siemens AG (Siemens Healthineers)
  • Bayer AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Randox laboratories limited

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Liver Disease Diagnostics Market, by End User
1.4.2 North America Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 North America Liver Disease Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Liver Disease Diagnostics Market by End User
3.1 North America Hospitals Market by Country
3.2 North America Laboratories Market by Country
3.3 North America Other End Users Market by Country
Chapter 4. North America Liver Disease Diagnostics Market by Diagnosis Technique
4.1 North America Imaging Market by Country
4.2 North America Biopsy Market by Country
4.3 North America Endoscopy Market by Country
4.4 North America Laboratory tests Market by Country
4.5 North America Other Diagnosis Techniques Market by Country
Chapter 5. North America Liver Disease Diagnostics Market by Country
5.1 US Liver Disease Diagnostics Market
5.1.1 US Liver Disease Diagnostics Market by End User
5.1.2 US Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Canada Liver Disease Diagnostics Market
5.2.1 Canada Liver Disease Diagnostics Market by End User
5.2.2 Canada Liver Disease Diagnostics Market by Diagnosis Technique
5.3 Mexico Liver Disease Diagnostics Market
5.3.1 Mexico Liver Disease Diagnostics Market by End User
5.3.2 Mexico Liver Disease Diagnostics Market by Diagnosis Technique
5.4 Rest of North America Liver Disease Diagnostics Market
5.4.1 Rest of North America Liver Disease Diagnostics Market by End User
5.4.2 Rest of North America Liver Disease Diagnostics Market by Diagnosis Technique
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10 Randox Laboratories Limited
6.10.1 Company Overview
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Boston Scientific Corporation
  • Siemens AG (Siemens Healthineers)
  • Bayer AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Randox laboratories limited
Note: Product cover images may vary from those shown

Loading
LOADING...